Three Jewish Scientists Behind Development of Drug Against Aids
Menu JTA Search

Three Jewish Scientists Behind Development of Drug Against Aids

Download PDF for this date

Three Jewish scientists are leading the development of a new drug that may provide hope for people with AIDS.

Professor Raymond Dwek, 47, of Oxford University’s Exeter College heads the Oxford Glycobiology Unit, which developed the drug, dubbed Oxaid.

Dr. Gary Jacob, 41, of New York, is director of the Searle support group, which works with the unit. The research is supported by Searle Pharmaceuticals, a subsidiary of the Monsanto Co.

The third scientist is Dr. Abraham Karpas, 51, who holds dual Israeli-British nationality and is assistant director of research at Cambridge University’s clinical school.

Karpas, a virologist, was the first person to identify the AIDS virus in Britain. He is testing the new compound.

Dwek explained that Oxaid works by altering the coating of the virus that causes AIDS, or acquired immune deficiency syndrome, an invariably fatal disease. “In a test tube, it’s a cure,” he told the Jewish Chronicle.

Founding Funders

The digitization of the JTA Archive would not have been possible without the generous support of the following donors:
  • The Gottesman Fund
  • Righteous Persons Foundation
  • Charles H. Revson Foundation
  • Elisa Spungen Bildner and Robert Bildner, in honor of Norma Spungen
  • George S. Blumenthal
  • Grace and Scott Offen Charitable Fund